Consensus Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
7.71 ^USD	+0.92%		-6.55%	+14.22%

May. 20	Cantor Fitzgerald Initiates Fulcrum Therapeutics at Overweight Rating With $23 Price Target	MT
May. 14	Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating	MT

Evolution of the average Target Price on Fulcrum Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6a6f67c93723791b06e1784.VmdkGlQGa6H3vs7qV__YQIMuQM8j8B84ipEalBrWkwk.IgYUImNOE-_H0a3HL6CLA9xeFb1gml1WzN5px3eJ8lYiADIuPGQR1r3h-g~d692378aa44b4b234c7f41c61cf573bd

Analyst Recommendations on Fulcrum Therapeutics, Inc.

Cantor Fitzgerald Initiates Fulcrum Therapeutics at Overweight Rating With $23 Price Target	May. 20	MT
Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating	May. 14	MT
Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15	May. 14	MT
Piper Sandler Adjusts Price Target on Fulcrum Therapeutics to $15 From $13, Maintains Overweight Rating	Feb. 28	MT
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $6 From $5, Maintains Neutral Rating	Jan. 25	MT
HC Wainwright Upgrades Fulcrum Therapeutics to Buy From Neutral, Adjusts Price Target to $14 From $5	23-08-23	MT
Stifel Upgrades Fulcrum Therapeutics to Buy From Hold, Raises Price Target to $11 From $4	23-08-22	MT
Oppenheimer Adjusts Fulcrum Therapeutics Price Target to $16 From $20, Maintains Outperform Rating	23-05-16	MT
HC Wainwright Adjusts Price Target on Fulcrum Therapeutics to $5 From $6, Maintains Neutral Rating	23-05-16	MT
Stifel Lowers Fulcrum Therapeutics' Price Target to $4 From $6, Hold Rating Kept	23-05-15	MT
Goldman Sachs Downgrades Fulcrum Therapeutics to Neutral From Buy, Adjusts Price Target to $3 From $9	23-05-04	MT
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $9 From $17, Maintains Buy Rating	23-03-13	MT
Stifel Downgrades Fulcrum Therapeutics to Hold From Buy, Adjusts Price Target to $6 From $35	23-03-10	MT
Morgan Stanley Adjusts Price Target on Fulcrum Therapeutics to $7 From $8, Maintains Equalweight Rating	23-03-10	MT
Credit Suisse Downgrades Fulcrum Therapeutics to Neutral From Outperform, Adjusts Price Target to $8 From $11	23-03-10	MT
HC Wainwright Downgrades Fulcrum Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $20	23-03-10	MT
Morgan Stanley Downgrades Fulcrum Therapeutics to Equalweight From Overweight, Adjusts Price Target to $8 From $27	23-02-28	MT
Oppenheimer Adjusts Fulcrum Therapeutics' Price Target to $20 From $26, Maintains Outperform Rating	23-02-27	MT
Credit Suisse Lowers Fulcrum Therapeutics' PT to $11 From $19, Says FTX-6058 Clinical Hold Introduces Near-Term Uncertainty; Keeps Outperform Rating	23-02-27	MT
Morgan Stanley Adjusts Price Target on Fulcrum Therapeutics to $27 From $26, Maintains Overweight Rating	23-01-24	MT
Piper Sandler Adjusts Price Target on Fulcrum Therapeutics to $21 From $18, Maintains Overweight Rating	23-01-23	MT
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $17 From $11, Maintains Buy Rating	23-01-19	MT
Goldman Sachs Starts Fulcrum Therapeutics at Buy With $11	22-11-15	MT
Morgan Stanley Adjusts Price Target on Fulcrum Therapeutics to $26 From $25, Maintains Overweight Rating	22-11-14	MT
Credit Suisse Adjusts Fulcrum Therapeutics' Price Target to $19 From $22, Keeps Outperform Rating	22-11-09	MT